SCHEMBL4073207

SCHEMBL4073207

CN(Cc1ccccc1)c1ncnc2cc(-c3ccccc3)sc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.53
LMNA P02545 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
PIK3CD O00329 1/20 0.52
PIK3R1 P27986 1/20 0.52
HTT P42858 1/20 0.52
HIF1A Q16665 1/20 0.52
CSF1R P07333 7/20 0.50
FLT1 P17948 3/20 0.50
EGFR P00533 3/20 0.50
POLB P06746 1/20 0.47
PDE5A O76074 1/20 0.44
MAP3K8 P41279 1/20 0.43
RPS6KB1 P23443 1/20 0.43
STK17B O94768 1/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TP53 P04637 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4068192 0.85 EGFR (0.59) IKBKBLMNASMN1; SMN2PIK3CDPIK3R1
SCHEMBL4065156 0.74 IKBKB (0.50) IKBKBLMNAFLT1EGFRPOLB
SCHEMBL4070018 0.74 IKBKB (0.50) IKBKBSMN1; SMN2FLT1EGFRPOLB
SCHEMBL5316797 0.74 GBA1 (0.58) LMNAHIF1ACSF1REGFRKDM4E
SCHEMBL4069660 0.73 IKBKB (0.41) IKBKBSMN1; SMN2FLT1EGFRMAP3K8
SCHEMBL16281232 0.73 IKBKB (0.67) IKBKBLMNASMN1; SMN2FLT1EGFR
SCHEMBL4075052 0.73 MAP3K8 (0.45) IKBKBCSF1RFLT1EGFRPOLB
SCHEMBL5316796 0.73 GBA1 (0.42) LMNASMN1; SMN2HIF1ACSF1REGFR
SCHEMBL14115081 0.72 IKBKB (0.61) IKBKBSMN1; SMN2FLT1EGFRMAP3K8
SCHEMBL3938279 0.72 FLT1 (0.46) IKBKBLMNASMN1; SMN2PIK3CDPIK3R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP claimed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
WO-2009007422-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-15 WO disclosed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 IKBKB 2889/4885LMNA 3392/4885SMN1; SMN2 2434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.